Through a meta-analysis of randomized controlled trials (RCTs), this research provides evidence-based insights into the comparative therapeutic benefits of these GLP-1 receptor agonists, with a particular focus on Semaglutide’s role in optimizing diabetes and obesity management. The gene discussed is GLP1R; the disease is obesity disorder.